News & Analysis on Clinical Trial Services & Contract Research And Development
With the bipartisan 21st Century Cures Act coming up for a vote Friday in the US House, the White House and others are raising a number of concerns over how the bill would be paid for and what it will actually do to speed new cures to market.
Massachusetts-based CRO Parexel has expanded its services and capabilities in model-based drug development (MBDD) via its Quantitative Clinical Development (QCD) unit.
The fanfare that accompanies Big Pharma strategic partnerships with CROs is rarely followed by progress reports according to an industry consultant, who warns the lack of feedback means mistakes are repeated.
With an overwhelming majority, the House on Friday morning passed a new bipartisan bill that would increase NIH funding by about $8.75bn and the FDA by $550m over the next five years.
Par Pharmaceuticals says it has addressed its temperature-control system at a Michigan facility after overheating caused the death of 39 guinea pigs.
An operational rejig at DPT Laboratories, an expansion at UDG, and a synthesis and toxicology testing contract win for Dalton – welcome to Outsourcing-Pharma’s CDMO round-up.